A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2, Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 960
- Population
- ALL · 50 Years
- Duration
- 2026-03-27 to 2028-06-30
- Intervention
- Tiespectus; Aflibercept
- Comparator
- Aflibercept 2 mg
- Outcomes measured
- Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From…; Mean Change in BCVA (ETDRS Letters) From Baseline (Day 1) Over Time to Year 1 — Up to Year 1; Proportion of Participants Who Gain ≥5 ETDRS Letters at Year 1 — Year 1; Proportion of Participants Who Gain ≥10 ETDRS Letters at Year 1 — Year 1; Proportion of Participants Who Gain ≥15 ETDRS Letters at Year 1 — Year 1; Proportion of Participants Who Lose ≥5 ETDRS Letters at Year 1 — Year 1; Proportion of Participants Who Lose ≥10 ETDRS Letters at Year 1 — Year 1; Proportion of Participants Who Lose ≥15 ETDRS Letters at Year 1 — Year 1; Mean Change in Spectral Domain Optical Coherence Tomography (SD-OCT) Central Subfield Thickness (CST) From Baseline (Da…; Number of Participants who Experience One or More Systemic Adverse Events (AEs) — Up to approximately 96 weeks; Number of Participants who Experience One or More Ocular AEs — Up to approximately 96 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.